Commentary on "CTLA-4 Blockade Suppresses Progression of Residual Tumours after Insufficient RFA"

Cardiovasc Intervent Radiol. 2020 Sep;43(9):1362-1363. doi: 10.1007/s00270-020-02564-9. Epub 2020 Jul 24.

Authors

B Geboers¹, M R Meijerink²

Affiliations

¹ Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers (location VUmc), de Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
² Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers (location VUmc), de Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. mr.meijerink@amsterdamumc.nl.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Animals
CTLA-4 Antigen
Carcinoma, Hepatocellular*
Humans
Liver Neoplasms*
Mice
Neoplasm, Residual
Radiofrequency Ablation*

Substances

CTLA-4 Antigen